Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotorasib

FDA-approved product (tablet, oral), marketed as Lumakras.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sotorasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotorasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotorasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

    NCT05550129 · start 2019-11-13

    Registered record
    Registry ID
    NCT05550129
    Conditions
    Healthy Volunteers
    Interventions
    AMG 510; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-13
    Completion
    2019-11-25
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAMG 510; Metformin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

    NCT05577624 · start 2019-11-05

    Registered record
    Registry ID
    NCT05577624
    Conditions
    Healthy Participants
    Interventions
    AMG 510; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-05
    Completion
    2019-12-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAMG 510; Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

    NCT04092673 · start 2019-10-25

    Registered record
    Registry ID
    NCT04092673
    Conditions
    Solid Tumor, Adult
    Interventions
    eFT226; Sotorasib; Fulvestrant; Abemaciclib; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-10-25
    Completion
    2025-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Adult
    InterventioneFT226; Sotorasib; Fulvestrant; Abemaciclib +1 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

    NCT03600883 · start 2018-08-27

    Registered record
    Registry ID
    NCT03600883
    Conditions
    KRAS p.G12C Mutant Advanced Solid Tumors
    Interventions
    sotorasib; Anti PD-1/L1; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-08-27
    Completion
    2026-05-29
    Enrolment
    713

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKRAS p.G12C Mutant Advanced Solid Tumors
    Interventionsotorasib; Anti PD-1/L1; Midazolam
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Expanded Access of Sotorasib

    NCT04667234

    Registered record
    Registry ID
    NCT04667234
    Conditions
    Non Small-cell Lung Cancer; Locally Advanced Unresectable NSCLC; Locally Advanced Metastatic NSCLC
    Interventions
    AMG 510
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small-cell Lung Cancer; Locally Advanced Unresectable NSCLC; Locally Advanced Metastatic NSCLC
    InterventionAMG 510
    PhaseNot recorded
    Registry statusNo longer available